Multiple myeloma · Autologous stem cell transplantation · Bisphosphonate-related osteonecrosis of the jaw · BRONJ · ONJ Summary Background: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe complication of bisphosphonate therapy. Due to their long survival and subsequently high cumulative doses of bisphosphonates, multiple myeloma patients have the highest risk of developing BRONJ of all patients treated with bisphosphonates. The purpose of the present study was to evaluate the incidence and risk factors for BRONJ in multiple myeloma patients after high-dose chemotherapy and autologous stem cell transplantation (ASCT). Patients and Methods: We retrospectively analyzed the data of 120 multiple myeloma patients after high-dose chemotherapy and ASCT treated with bisphosphonates and assessed the incidence and risk factors of BRONJ. Results: Of the 120 patients, 23 (19%) developed BRONJ. 6 patients suffered several BRONJ events, resulting in a total incidence of 23%. The risk for BRONJ was significantly higher for patients with rheumatism and recent dental manipulations. Furthermore, the number of previous bisphosphonate rotations, the duration of bisphosphonate therapy, and the type and cumulative dose of bisphosphonate used were associated with the incidence of BRONJ. Conclusion: Our study is the first to determine the risk of BRONJ in a homogeneous group of multiple myeloma patients treated with high-dose chemotherapy and ASCT.
The purpose of the present study was to evaluate the incidence and risk factors for BRONJ in multiple myeloma patients after high-dose chemotherapy and autologous stem cell transplantation (ASCT).
Patients and Methods:
We retrospectively analyzed the data of 120 multiple myeloma patients after high-dose chemotherapy and ASCT treated with bisphosphonates and assessed the incidence and risk factors of BRONJ. Results: Of the 120 patients, 23 (19%) developed BRONJ. 6 patients suffered several BRONJ events, resulting in a total incidence of 23%. The risk for BRONJ was significantly higher for patients with rheumatism and recent dental manipulations. Furthermore, the number of previous bisphosphonate rotations, the duration of bisphosphonate therapy, and the type and cumulative dose of bisphosphonate used were associated with the incidence of BRONJ. Conclusion: Our study is the first to determine the risk of BRONJ in a homogeneous group of multiple myeloma patients treated with high-dose chemotherapy and ASCT. breast cancer and multiple myeloma [15, [22] [23] [24] [25] [26] . In the presentstudy,weexaminedtheincidenceandriskfactorsof BRONJ in 120 multiple myeloma patients after high-dose chemotherapy and autologous stem cell transplantation (ASCT).
Patients and Methods

Patients and Determination of BRONJ
We retrospectively analyzed the data of 120 patients with multiple myeloma undergoing high-dose chemotherapy and ASCT from 2003 until 2008. The patients received melphalan at a dose between 140 and 200 mg/m 2 . Reinfusion of autologous peripheral blood stem cells was performed48haftertheendofchemotherapy.Allpatientsreceivedthe same supportivecare.Redbloodcellproductsandsingle-donorplatelets were substituted to maintain a hemoglobin level above 80 g/l and a platelet count above 10,000/ml. All patients were assessed by a maxillofacialsurgeonoradentistpriortohigh-dosechemotherapy.Pamidronate at30,60or90mg,zoledronicacidat2,3or4mg,andibandronateat2,4 or6mgwereadministeredintravenouslyevery4weeks,whereasclodronateat800or1600mgwasappliedorallydaily.Timeofexposuretobisphosphonates was defined as the time in months from the initial to the lastrecordedadministration.Everypatientwhohadundergonehigh-dose chemotherapyandwastreatedwithbisphosphonatesinourcenterhadan oralexaminationateachmonthlycontrolvisit.Incasedentalmanipulationsbecamenecessary,bisphosphonateswerediscontinuedfor1month untilwoundhealingwasconfirmed.ThediagnosisofBRONJwasmade according to its definition (exposed bone over a period of 8 weeks, no history of irradiation of the jaw bones, and positive medical history for bisphosphonateadministration) [18, 19] andconfirmedbyanexperienced maxillofacial surgeon. The treatment was performed according to the guidelinesoftheAmericanAssociationofOralandMaxillofacialSurgery [18] . 6 patients suffered 2 independent BRONJ events at different sites andtimes,partiallyunderdifferentbisphosphonatetreatmentregimens. Thesecaseswerecalculatedas2BRONJeventseach.
Statistical Analysis
ThepatientgroupwithBRONJevents(n=29)wascomparedtothepatientgroupwithoutBRONJ(n=97).Forstatisticalanalyses,weusedthe SPSS program, the Fisher-Yates test, and the Mann-Whitney U test; pvalues<0.05wereconsideredasstatisticallysignificant.
Results
Patient Characteristics
Thebaselinecharacteristicsof120multiplemyelomapatients includedintheanalysisarelistedintable1.Themeanfollowuptimewas62.9(±38.8)monthsafterthediagnosisofmultiplemyeloma,46.3(±30.4)monthsafterthefirstASCTand 35.4 (± 27.1) months after the last ASCT. Of 120 patients, 23 (19%) developed BRONJ. 6 patients suffered 2 BRONJ events at a different time and site, resulting in a total incidence of 29 events (23%). The mean time between the last ASCTandBRONJwas38.4(±27.6)months.Themajorityof patients(62%)hadosteonecrosisofthemandible.Therewere nosignificantdifferencesinpatientgender,ageatdiagnosisof multiplemyeloma,bodymassindex,diseasestage,andpresIntroduction Osteolyticmetastasesareprimarilycausedbyexcessivebone resorptionthroughosteoclastswithconcurrentlyimpairedosteoblast function. This is due to a variety of cytokines producedbymetastaticcancercellsthatcaninfluencebothosteoclast and osteoblast function [1] . A remedy to alleviate the effectsofexcessiveboneresorptionistreatmentwithbisphosphonates.Bisphosphonatesaresyntheticpyrophosphateanalogs that generate cytotoxic effects on different cells, and in particularonosteoclastsbecausetheyaccumulateinthiscell type, interfere with various pathways and subsequently reduce osteoclast activity, adhesion and migration ability and induce apoptosis and/or necrosis [2] [3] [4] [5] . According to their chemical structure, bisphosphonates are subdivided into 4groups:bisphosphonateswithoutnitrogensubstitution(e.g. etidronate,clodronate),aminobisphosphonates(e.g.pamidronate, alendronate), aminobisphosphonates with substitution ofthenitrogenatom(e.g.ibandronate),andbisphosphonates with basic heterocycles containing nitrogen (e.g. zoledronic acid).Theintroductionofthenitrogenpositionincreasedthe antiresorptivepotency.Themolecularmechanismsofaction vary between different bisphosphonates: Bisphosphonates without nitrogen form a toxic ATP analog that inhibits the mevalonate pathway. Nitrogen-containing bisphosphonates inhibitmultiplecellularpathwaysrelatedtointegrinsignaling andapoptosisandalsothemevalonicacidmetabolicpathway andtheprenylationofsmallGTPasesignalingproteins [6] .
Beside their beneficial effects on pain and reduction of fractures [7] ,bisphosphonatesmayalsodisplayantimyeloma andantitumoractivity [8] [9] [10] [11] .Event-freeandoverallsurvival arebothimprovedinpatientstreatedwithbisphosphonates, whichhasparticularlybeenshownforthenitrogen-containing bisphosphonate zoledronic acid [12, 13] . Thus, bisphosphonateshavebecomeanimportantcomponentofthesupportive careofpatientswithmultiplemyelomaorsolidtumorswith bonemetastases.Adverseeffectsareinfrequentandareprimarilyconstitutedbyacute-phasereactions,complicationsof the upper aerodigestive tract such as esophageal ulceration, hypocalcemia, and impaired renal function [14] . However, firstdescribedin2003,bisphosphonate-relatedosteonecrosis ofthejaw(BRONJ)hasemergedasaseverecomplicationof bisphosphonate therapy [15] [16] [17] . BRONJ is defined by an areaofexposedboneinthemandibleormaxillaoveraperiod exceeding 8 weeks, in patients with current or previous bisphosphonateintakeandwithouthistoryofirradiationofthe jaw bone [18, 19] . The exposed bone may be asymptomatic or associated with pain, infection, or further complications suchasnerveimpairmentorpathologicalfractures.BRONJ predominantlyaffectspatientsreceivingintravenousadministrationsofnitrogen-containingbisphosphonatesduetomalignantunderlyingdiseases.TheestimateofthecumulativeincidenceofBRONJinthesepatientsrangesfrom0.8to20.5% [20, 21] ,butthehighestincidencewasfoundinpatientswith Then/Hörauf/Otto/Pautke/vonTresckow/ Röhnisch/Baumann/Schmidmaier/ Bumeder/Oduncu enceofosteolyticlesionsatfirstdiagnosis.However,patients whodevelopedBRONJweresignificantlyolderatthetimeof datacollection,reflectingalongerdiseasecourseandconsequently a longer exposure time to bisphosphonates. No significant differences were detected in the use of prednisone, dexamethasone,bortezomib,thalidomide,cyclophosphamide, bendamustineandlenalidomide,themelphalandoseorradiation therapy between patients with and without subsequent BRONJ.
Patient-Related Risk Factors for BRONJ
TheincidenceofBRONJwasstronglyassociatedwithrheumatism:31%ofthepatientswithBRONJsufferedfromrheu-maticdisease(rheumatoidarthritisorankylosingspondylitis), comparedtoonly4.1%oftheno-BRONJcases(p=0.0001). Recent dental manipulations (dental extractions, root canal surgery,placementofdentalimplants)hadoccurredin19of 29BRONJevents(65.5%),comparedto20oftheno-BRONJ cases (20.6%). There was no association of anemia, osteoporosis,diabetesmellitus,andrenalfailurewiththedevelopmentofBRONJ( fig.1 ).Mproteinandbeta-2-microglobulin weresimilarinpatientswithandwithoutBRONJ;however, theplasmaalbuminconcentrationwashigherinpatientswith BRONJ events (4.7 ± 2.7 g/dl; range 3.4-16.5 g/dl) as comparedtopatientswithoutBRONJ(3.6±0.7g/dl;range2.0-4.7g/dl;p=0.01,datanotshown).Furthermore,themeanCreactiveprotein(CRP)valuedirectlyprecedingtheBRONJ eventswaselevatedto1.6±2.7mg/dl(normal<0.5mg/dl).
Duration and Type of Bisphosphonate Therapy and Incidence of BRONJ
The total duration of bisphosphonate treatment was significantly longer in patients who developed BRONJ ( fig. 2A) fig. 2C ). TherewasatrendforhigherBRONJriskforpatientsreceiving zoledronic acid than for patients treated with pamidronate.TheBRONJriskwassignificantlyelevatedforpatients treated with zoledronic acid compared to patients treated withibandronate( fig.2D ).BRONJoccurredin39.1%ofpa-tientscurrentlyreceivingzoledronicacid(n=28),in22.6%of patientsreceivingpamidronate(n=31),in14.8%ofpatients treated with ibandronate (n = 54), and additionally in both patients receiving zoledronic acid and pamidronate alternatively (n = 2) and in 1 patient receiving clodronate (n = 1). The remaining patients without BRONJ had stopped the bisphosphonatetreatmentbeforedatacollection.Notably,no BRONJ event occurred under ibandronate alone. Patients who developed BRONJ under current treatment with ibandronate were in 75% (n = 6) of the events pretreated with zoledronicacidandin87.5%(n=7)oftheeventspretreated withpamidronate( fig.2E) . Furthermore, the incidence of BRONJ was significantly associatedwiththenumberofpreviousbisphosphonaterotations (p = 0.013; fig. 3 ). Whereas in only 6 of 29 BRONJ events (20.7%) the bisphosphonate therapy had not been changed prior to the development of BRONJ, in 8 BRONJ cases(27.6%)thebisphosphonatetherapyhadbeenchanged once,in7cases(24.1%)twice,in5cases(17.2%)3-5times, and 3 patients with BRONJ (10.3%) had undergone 10 or morerotationsofthebisphosphonatetherapy.Ofthepatients without BRONJ, 44.3% (43 no-BRONJ events) had had no rotation of the treatment, 33.0% (32 cases) 1 rotation and 15.5%(15cases)2rotations.Only7no-BRONJcases(7.2%) hadundergone3ormorebisphosphonaterotations.
Discussion
Thepresentstudyidentifiesmultiplemyelomapatientsafter high-dosechemotherapyandASCTashigh-riskpatientsfor BRONJ.PreviousstudiesdemonstratedthatBRONJisespeciallyfrequentinmultiplemyelomapatientswithareported incidence of 1.7-20.5% [21, 25, 26] . The reason for this is probably the long treatment duration with high cumulative bisphosphonate doses, since myeloma patients are often affectedbypathologicalbonefracturesearlyintheirdisease course but still have a long survival compared to other patientswithbonemetastases.Thetimeperiodofbisphosphonate treatment and the cumulative dose have emerged as valid risk factors for BRONJ [26] [27] [28] . The Mayo clinic consensus statement and the International Myeloma Working Group(IMWG)guidelinesrecommendreductionofbisphosphonate use to 1 or 2 years in patients reaching a plateau phaseorcompleteresponse.Forpatientswithactivedisease, Then/Hörauf/Otto/Pautke/vonTresckow/ Röhnisch/Baumann/Schmidmaier/ Bumeder/Oduncu therapyfrequencycanbedecreasedtoevery3monthsafter 2years [29, 30] .ThehighincidenceofBRONJevents(23%) in our study group of multiple myeloma patients after highdosechemotherapyandASCTispossiblyexplainedbyalong disease course and a long bisphosphonate exposure (33.5 months for patients without BRONJ and 55 months for patients with BRONJ). Furthermore, the patients in our study grouphadallundergoneaggressivehigh-dosechemotherapy followed by neutropenia, and had mostly been treated with multiplechemotherapyregimensduringtheirdiseasecourse. Chemotherapy generally has immunosuppressant and antivasculogenic properties, which might be even more intense afterhigh-dosechemotherapy.Effectsofstemcelldepletion induced by high-dose chemotherapy on later wound healing capacityandriskofBRONJcannotbeexcluded,andaggressive or multiple chemotherapies may therefore facilitate adverseeventssuchasBRONJ.
Other (but inconsistently described) BRONJ risk factors areanthracyclines,melphalan,thalidomide,patientage,obesity,diabetes,smoking,alcoholuse,renalinsufficiency,erythropoietin, and glucocorticoids [24-26, 31, 32] . In the present study, BRONJ was not related to obesity, diabetes mellitus, anemia,renalfailure,thepreviouschemotherapyregimen,or theuseofglucocorticoids.Incontrast,dentalextraction,mandibular tori, sharp mylohyoid ridges, and dental infections suchasendodontitis,periodontitis,caries,orabscessedteeth are recognized risk factors [15, 21, 26, 33] . These conditions theoreticallyresultinlocalaccumulationofbisphosphonates duetoincreasedpotentialbindingsitesduringboneremodeling,butalsoinanacidicmilieuinwhichnitrogen-containing bisphosphonates are released into their soluble, active state [34, 35] . Preventive measures like dental procedures proved beneficialwhenconductedwithenoughtimeforhealingbefore start of the bisphosphonate therapy [36] . However, although patients treated with high-dose chemotherapy and ASCTinourcenterundergodentalstatusevaluationpriorto treatment,dentalmanipulationduetolocaldentalinfections precededBRONJintwo-thirdsofcases,whichisinlinewith otherstudies [37] .
Furthermore, patients treated with zoledronic acid or pamidronate developed BRONJ more frequently and earlier comparedtopatientsreceivingibandronate.Notably,nocase ofBRONJoccurredunderibandronatealone.Thiscannotbe explainedbytherelativepotencyofthedifferentbisphosphonatestoinhibitboneremodelingalone(etidronate1,clodronate 10, pamidronate 100, ibandronate 10,000, zoledronate 100,000) [6, 12, 38] ,butmightalsobeduetothedifferentpKa valuesofthebisphosphonates,whichinfluencetheiractivity indifferentpHmilieusaswellastheirreleasepropertiesfrom thebone-boundintothesolubleform [34] .Acidicmilieuslead to protonated activation of nitrogen-containing groups, therebyincreasingtheactivityofnitrogen-containingbisphosphonates. At the physiological pH of 7.4, zoledronic acid is theoreticallyprotonatedtoabout50%,whereasibandronate is not [39] . Inflammation generally decreases the pH level and,interestingly,theincidenceofBRONJinourstudygroup wasassociatedwithanelevatedCRPvalueandrheumatism,a conditionthatisaccompaniedbychronicinflammation,especiallyinthevicinityofbones.Thisisinlinewithinvestigations thatBRONJisoftenprecededbylocalinflammations [40, 41] . Therefore,thepresenceofrheumatismandespeciallychronic inflammatoryconditionsofthejawboneshouldbecarefully evaluatedandtreatedpriortoadministrationofbisphosphonates. Nevertheless, the antiresorptive effect itself seems to play a major role since denosumab, a monoclonal antibody whoseefficacyinpreventingskeletal-relatedeventswasdemonstratedtobeatleastequaltozoledronate,hasalsoshowna similarBRONJrisk [42] .
Despite a higher BRONJ incidence in patients receiving zoledronicacid,ithastobetakenintoaccountthatzoledronic acidhasbeendemonstratedtobesuperiortothenon-nitrogen-containing clodronate not only in reducing skeletal-relatedevents,butalsoindecreasingoverallmortality [43, 44] . Thisobservationisconsistentwithpreclinicaldataindicating that especially nitrogen-containing bisphosphonates might have inherent anticancer activities independently of their effectonbone [43, 45] ,whichdependoninhibitionofprotein phenylation, a mechanism not shared by non-nitrogencontainingbisphosphonates [8, 44] .Pamidronatedisplayeda non-significant trend towards a lower BRONJ frequency as comparedtozoledronicacidinthepresentstudy.However,it has previously been demonstrated that zoledronic acid was superiortopamidronateinpreventingskeletal-relatedevents atleastincertainsubsetsofpatients [46] .Sinceibandronate,a nitrogen-containing bisphosphonate with high antiresorptive properties, is not approved for treatment of myeloma patients,datarelatingtoibandronateuseinmyelomapatientsis sparse. However, a metaregression analysis has suggested a borderlinesignificanttrendforoverallsurvivalbasedonthe bisphosphonate potency, although overall survival does not seemtobedifferentcomparingzoledronicacid,pamidronate, andibandronate [13] .Sinceourstudydemonstratedalower BRONJ risk associated with ibandronate in myeloma patients, further investigations concerning the efficacy and safety of ibandronate in myeloma patients are desirable. Changing the regimen from zoledronic acid to another bisphosphonatemaybeatheoreticaloptionifdentalprocedures becomenecessary.However,inourstudy,patientsundergoingseveralchangesinthebisphosphonateregimenhadanincreased risk of BRONJ, and pretreatment with zoledronic acidorpamidronatewasassociatedwithBRONJevenaftera switch to ibandronate. The higher BRONJ risk for patients havingundergonebisphosphonaterotationsneedsfurtherinvestigation. Possible explanations range from inadvertencies duringchangingoftheregimen,suchaspossibleoverdosage becausetimeintervalsmaynothavebeenmetaccurately,to the different mechanisms of action of different bisphosphonate types, which may overlap due to their long binding to bone, possibly further decreasing the bone remodeling capacity [6] .Notably,inmostcases,thecauseforthechange of bisphosphonate treatment was trivial or not apparent. However,ourdatademonstratesthatunfoundedrotationsin thebisphosphonatetreatmentregimenshouldbeavoided.
In conclusion, this data demonstrates that myeloma patients having undergone ASCT are at high risk for BRONJ. Treatment-related factors increasing this risk are the use of zoledronic acid, a long duration of bisphosphonate therapy, androtationsofthebisphosphonateregimen.Patient-related factorsareconditionsaccompaniedbyinflammation,suchas rheumatism or recent dental manipulation. Once identified, certain risk factors for BRONJ, in particular changes in the bisphosphonateregimen,canbeeasilyavoided.Forpatients athighriskforBRONJ,bisphosphonatesshouldbeusedwith care and treatment frequency and duration should be reconsidered.
Disclosure Statement
Theauthorsdeclarenocompetingfinancialinterests.
